BOSTON, March 24 (Reuters) - Biogen Idec Inc has acquired an option to license the rights to certain experimental cancer drugs being developed by privately held Aveo Pharmaceuticals Inc. Sign up here.
AVEO Acquires Clinical Stage Anti-Cancer Compound From Kirin - AVEO adds Phase II-ready VEGF receptor inhibitor to growing product portfolio - CAMBRIDGE, Mass., January 04, 2007 -- AVEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback